Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Surg Oncol. 2013 Feb;107(2):180-7. doi: 10.1002/jso.23255. Epub 2012 Sep 4.
(18) F-fluorodeoxyglucose ((18) F-FDG) uptake may identify poorly differentiated tumors with a high proliferation rate that are more responsive to neoadjuvant chemotherapy.
We retrospectively evaluated 273 patients (mean age, 44.2 years; range 23-78 years) newly diagnosed with stage II or III invasive ductal breast cancer between 2006 and 2010. All patients were treated with neoadjuvant chemotherapy followed by surgery. The ability of parameters to predict pathological complete response (pCR), was assessed by multivariate analysis.
Of the 273 breast cancer patients, 30 (11.0%) achieved pCR. Univariate analysis revealed that higher histologic grade (P < 0.001), lack of estrogen receptor (ER, P < 0.001); and a higher maximal standardized uptake value (SUVmax, P < 0.001) were associated with pCR, whereas HER2/neu amplification and Ki-67 expression were not (P > 0.05 for each comparison). Multivariate analysis showed that negative ER (odds ratio [OR] = 9.98; 95% confidence interval [CI], 2.88-34.52, P < 0.001) and the SUVmax of (18) F-FDG uptake (OR per one unit increase in SUVmax = 1.09; 95% CI, 1.02-1.16, P = 0.008) were independent predictors of pCR.
ER status and (18) F-FDG uptake are independent predictors of pCR after neoadjuvant chemotherapy for breast cancer.
（18）氟-脱氧葡萄糖（（18）F-FDG）摄取可能识别出增殖率较高的低分化肿瘤，这些肿瘤对新辅助化疗更敏感。
我们回顾性评估了 273 例 2006 年至 2010 年间新诊断为 II 期或 III 期浸润性导管乳腺癌的患者（平均年龄 44.2 岁；范围 23-78 岁）。所有患者均接受新辅助化疗后行手术治疗。采用多变量分析评估参数预测病理完全缓解（pCR）的能力。
在 273 例乳腺癌患者中，30 例（11.0%）达到 pCR。单因素分析显示，较高的组织学分级（P < 0.001）、缺乏雌激素受体（ER，P < 0.001）和较高的最大标准化摄取值（SUVmax，P < 0.001）与 pCR 相关，而 HER2/neu 扩增和 Ki-67 表达则无相关性（每一次比较的 P 值均大于 0.05）。多因素分析显示，ER 阴性（比值比 [OR] = 9.98；95%置信区间 [CI]，2.88-34.52，P < 0.001）和（18）F-FDG 摄取的 SUVmax（SUVmax 每增加一个单位的 OR = 1.09；95%CI，1.02-1.16，P = 0.008）是 pCR 的独立预测因子。
ER 状态和（18）F-FDG 摄取是乳腺癌新辅助化疗后 pCR 的独立预测因子。
